When Everything Revolves Around Internal Carotid Artery: Analysis of Different Management Strategies in Patients With Very Advanced Cancer Involving the Skull Base.
cancer
carotid
encasement
head & neck
involvement
skull base (head and neck)
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
09
2021
accepted:
02
11
2021
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
7
12
2021
Statut:
epublish
Résumé
Internal or common carotid artery encasement (CAE) is observed in almost 2-7% of head and neck cancers (HNC) and designates the tumor with the T4b category. This clinical scenario is associated with a dismal prognosis, owing to the risk for thrombosis and bleeding that usually characterizes such an advanced cancer. Standardized radiological criteria to infer invasion of the carotid artery are lacking. Complete surgical resection in the context of a multimodality treatment is supposed to offer the greatest chances of cure. Surgery can either be carotid-sparing or include carotidectomy. Data on probability of cerebrovascular and non-cerebrovascular complications, risk of carotid blowout, poor oncologic outcomes, and less-than-certain efficacy of diagnostic and interventional preventive procedures against cerebral infarction make it difficult to define surgery as the recommended option among other therapeutic strategies. Non-surgical therapies based on radiation therapy possibly combined with chemotherapy are more frequently employed in HNC with CAE. In this context, carotid blowout is the most feared complication, and its probability increases with tumor stage and cumulative radiation dose received by the vessel. The use of highly conformal radiotherapies such as intensity-modulated particle therapy might substantially improve the manageability of HNC with CAE by possibly reducing the risk of late sequalae. Despite evidence is frail, it appears logical that a case-by-case evaluation through multidisciplinary decision making between head and neck surgeons, radiation oncologists, medical oncologists, diagnostic and interventional radiologists, and vascular surgeons are of paramount value to offer the best therapeutic solution to patients affected by HNC with CAE.
Identifiants
pubmed: 34869033
doi: 10.3389/fonc.2021.781205
pmc: PMC8636461
doi:
Types de publication
Journal Article
Langues
eng
Pagination
781205Informations de copyright
Copyright © 2021 Orlandi, Ferrari, Lafe, Preda, Benazzo, Vischioni, Bonora, Rampinelli, Schreiber, Licitra and Nicolai.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neurosurg Focus. 2003 Mar 15;14(3):e6
pubmed: 15709723
Am J Otolaryngol. 2001 May-Jun;22(3):167-71
pubmed: 11351284
Head Neck. 2014 Feb;36(2):215-9
pubmed: 23554082
Acta Otolaryngol. 2002 Jul;122(5):561-4
pubmed: 12206270
Neurosurg Focus. 2003 Mar 15;14(3):e5
pubmed: 15709722
JAMA Otolaryngol Head Neck Surg. 2013 Nov;139(11):1219-25
pubmed: 24077023
Radiology. 1995 Jun;195(3):715-20
pubmed: 7754000
Otolaryngol Head Neck Surg. 2001 Feb;124(2):222-4
pubmed: 11226961
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 May;109(5):775-8
pubmed: 20416537
Laryngoscope. 2004 Jan;114(1):20-4
pubmed: 14709989
Head Neck. 2019 Sep;41(9):3073-3079
pubmed: 31070287
Oral Oncol. 2020 Jul;106:104803
pubmed: 32410826
Int J Clin Oncol. 2015 Jun;20(3):455-62
pubmed: 25248339
Laryngoscope. 2000 Mar;110(3 Pt 1):386-90
pubmed: 10718424
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):639-646
pubmed: 29413278
Eur J Radiol. 1993 Nov;17(3):191-4
pubmed: 8293747
Ann Otol Rhinol Laryngol. 2002 Sep;111(9):772-7
pubmed: 12296329
World Neurosurg. 2018 Nov;119:89-96
pubmed: 30075273
Cancer Manag Res. 2018 Nov 13;10:5617-5628
pubmed: 30519108
Acta Otolaryngol. 2008;128(12):1370-4
pubmed: 18607928
Cancers (Basel). 2020 Oct 17;12(10):
pubmed: 33080914
Radiother Oncol. 2015 Feb;114(2):182-8
pubmed: 25640299
Int J Oral Maxillofac Surg. 2003 Dec;32(6):645-50
pubmed: 14636618
Neurosurgery. 2008 Jun;62(6 Suppl 3):1373-408; discussion 1408-10
pubmed: 18695558
Braz J Otorhinolaryngol. 2008 Jan-Feb;74(1):79-84
pubmed: 18392506
Oral Oncol. 2019 Nov;98:35-47
pubmed: 31536844
Arch Otolaryngol Head Neck Surg. 1995 Sep;121(9):1029-33
pubmed: 7646855
AJNR Am J Neuroradiol. 1995 Aug;16(7):1453-8
pubmed: 7484632
Int J Surg Oncol. 2013;2013:968758
pubmed: 23431430
Jpn J Clin Oncol. 2014 May;44(5):428-34
pubmed: 24620027
Ann Oncol. 2017 Sep 1;28(9):2206-2212
pubmed: 28911070
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e813-8
pubmed: 21300455
Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):803-811
pubmed: 31349059
Acta Otolaryngol. 2015 Mar;135(3):302-6
pubmed: 25649887
World Neurosurg. 2014 Dec;82(6):1264-70
pubmed: 23994071
Ann Oncol. 2018 May 1;29(5):1130-1140
pubmed: 29635316
J Neurosurg. 2013 Mar;118(3):637-42
pubmed: 23082880
Arch Otolaryngol. 1974 Apr;99(4):235-41
pubmed: 4131800
Head Neck. 2016 Apr;38 Suppl 1:E961-9
pubmed: 25993910